KDR and neoplasm: Other mechanisms that should be considered include a requirement for VEGFR2 signaling carried out by immune progenitors, or by one or more tumor-associated cells, including stromal and endothelial cells, or perhaps the tumor cells themselves, for attraction of the innate immune cells to the drug-treated tumors.